Eli Lilly stock slips despite steady GLP-1 script growth By Investing.com

Eli Lilly shares fell 2% after mixed weekly GLP-1 prescription data showed Mounjaro rising to about 758,400 total prescriptions while Zepbound slipped to 615,300. Combined prescriptions for Lilly’s GLP-1 franchise were down 0.3% week over week, though the company held roughly 59% weekly new prescription share. Morgan Stanley said it sees about 6% upside to 2026 Mounjaro/Zepbound estimates, but the launch data for Foundayo remained modest at about 3,700 prescriptions in its second week.

Analysis

The key read-through is not that Lilly is losing share, but that the cadence of growth is normalizing just as the market is looking for evidence that the next leg of GLP-1 expansion can support premium expectations. A flat-ish weekly share print with softer Zepbound net adds suggests the category is transitioning from scarcity-driven acceleration to more elastic demand, where prescription growth becomes more sensitive to payer access, refill continuity, and dose escalation rather than pure new patient conversion.

That matters for suppliers and competitors in different ways. IQVIA-based weekly data can move sentiment on Lilly and Novo near term, but the second-order winners are likely the channel operators and data intermediaries that benefit from more volatile monitoring demand, while the first casualty is the multiple on the obesity complex if investors start underwriting every week as a data point rather than a trend. The launch comparison for Foundayo is also instructive: the market may be overestimating how quickly a new oral entrant can meaningfully cannibalize injectables when physician behavior, titration, and patient persistence create a long adoption curve.

The bigger contrarian point is that the move looks tactically overdone unless the weekly trend persists for several reads. A 2% pullback on a modest deceleration in aggregate prescriptions is more about positioning than fundamentals; the real risk is not this week’s print, but whether payer pressure or competitive discounting forces a lower terminal growth assumption over the next 6-12 months. If that happens, the whole GLP-1 basket de-rates together, but if weekly growth re-accelerates, today’s dip becomes a buying opportunity.

For now, the cleanest setup is to fade the reflex selloff while using catalysts to hedge. The data still supports a structurally large obesity market, but the cadence suggests investors should stop extrapolating linear weekly gains into 2027 growth rates.

Key Decisions for Investors

• Buy LLY on weakness over the next 1-3 trading sessions; use a tight stop below the post-data low because the setup is sentiment-driven, not thesis-breaking. Upside is a mean reversion back to the pre-print range if follow-on weekly data is merely stable.
• Sell short-dated downside puts on LLY only if implied volatility remains elevated after the open; prefer structures with limited assignment risk because the data risk is weekly and headline-sensitive.
• Pair trade: long LLY / short a GLP-1 basket proxy on strength in the group, with a 2-6 week horizon. The idea is to own the franchise with the deepest demand durability while fading names more exposed to launch disappointment or pricing pressure.
• Avoid adding to momentum longs in the obesity trade until at least 2-3 more weekly prints confirm whether Zepbound stabilization is real. The risk/reward is poor for chasing after a single soft week.
• For more aggressive accounts, consider a modest LLY call spread expiring in 1-3 months: it captures re-rating if the market over-discounts the weekly data, while capping premium outlay if payer headlines worsen.